A Proteomic Co-Clinical Trial of BGJ-398 in FGFR Driven Biliary Cancers
Abstract
Oncogenic fibroblast growth factor receptor (FGFR) signaling drives a subset of lung, liver, stomach, brain, and bladder cancers. FGFR is activated by a number of genetic mechanisms, including amplification, fusion and point mutation. Despite years of effort by academic and pharmaceutical investigators, we are only now beginning to see efficacy with FGFR-targeted therapy. One key area of progress is the targeting of oncogenic FGFR2 fusions in tumors arising in the biliary tract of the liver.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2018
- Accession Number
- AD1060894
Entities
People
- Nabeel Bardeesy